News about Unity Biotechnology Inc

UNITY Biotechnology Continues Strategic Leadership Investment as Share Price Surges by 58.77% in 2025
Jan 07 2025
South San Francisco, Calif. - January 7, 2025 - UNITY Biotechnology, Inc. NASDAQ: UBX, a pioneering force in therapeutic development aimed at combati...

UNITY Biotechnology Grants Stock-Based Award to New Chief Strategy Officer, Impacting Shareholders
Jul 24 2024
SOUTH SAN FRANCISCO, Calif., July 24, 2024 - UNITY Biotechnology, Inc. (UNITY) NASDAQ: UBX, a pioneering biotechnology company renowned for its e...

UNITY Biotechnology Advances Phase 2b ASPIRE Study, Pioneers New Therapeutic Approach for Diabetic Macular Edema
Apr 23 2024
UNITY Biotechnology Extends Phase 2b ASPIRE Clinical Study for UBX1325 in DME, Aiming to Enhance Durability and Statistical PowerSOUTH SAN FRANCISCO, ...

Pioneering Vision: Senolytic Therapies Reveal Revolutionary Possibilities for Vision Loss Treatment
Feb 06 2024
In the ever-evolving world of biopharmaceuticals, breakthrough achievements occasionally redefine our understanding of disease treatment and managemen...

A Bold Leap Forward: UNITY Biotechnology Begins Phase 2 Trials of Vision impairment Drug UBX1325 with Promising Outlook for 2024
Dec 12 2023
UNITY Biotechnology has marked a significant stride in its ambitious endeavor to combat vision impairment. The company, renowned for developing t...

Breaking News: Unity Biotechnology Inc. Reveals Shocking Operating Shortfall of $-14.931 Million in Recent Report!
Nov 14 2023
The latest financial report from Unity Biotechnology Inc for the third quarter of 2023 has raised some concerns among industry advisors. The...